Search

Your search keyword '"Tinker, Anna V."' showing total 329 results
Start Over Author "Tinker, Anna V."
329 results on '"Tinker, Anna V."'

1. Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial

Author

Valabrega, Giorgio, Pothuri, Bhavana, Oaknin, Ana, Graybill, Whitney S., Sánchez, Ana Beatriz, McCormick, Colleen, Baurain, Jean-François, Tinker, Anna V., Denys, Hannelore, O’Cearbhaill, Roisin E., Hietanen, Sakari, Moore, Richard G., Knudsen, Anja Ør, de La Motte Rouge, Thibault, Heitz, Florian, Levy, Tally, York, Whitney, Gupta, Divya, Monk, Bradley J., and González-Martín, Antonio

Published
2024
Full Text
View/download PDF

3. A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors

Author

Bauer, Todd M., Moore, Kathleen N., Rader, Janet S., Simpkins, Fiona, Mita, Alain C., Beck, J. Thaddeus, Hart, Lowell, Chu, Quincy, Oza, Amit, Tinker, Anna V., Imedio, Esteban Rodrigo, Kumar, Sanjeev, Mugundu, Ganesh, Jenkins, Suzanne, Chmielecki, Juliann, Jones, Suzanne, Spigel, David, and Fu, Siqing

Published
2023
Full Text
View/download PDF

4. Targeting HER2-mutant metastatic cervical cancer with neratinib: Final results from the phase 2 SUMMIT basket trial

Author

Friedman, Claire F., D'Souza, Anishka, Bello Roufai, Diana, Tinker, Anna V., de Miguel, Maria, Gambardella, Valentina, Goldman, Jonathan, Loi, Sherene, Melisko, Michelle E., Oaknin, Ana, Spanggaard, Iben, Shapiro, Geoffrey I., ElNaggar, Adam C., Panni, Stefano, Ravichandran, Vignesh, Frazier, Aimee L., DiPrimeo, Daniel, Eli, Lisa D., and Solit, David B.

Published
2024
Full Text
View/download PDF

5. Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2

Author

Konecny, Gottfried E, Oza, Amit M, Tinker, Anna V, Oaknin, Ana, Shapira-Frommer, Ronnie, Ray-Coquard, Isabelle, Aghajanian, Carol, Coleman, Robert L, O'Malley, David M, Leary, Alexandra, Chen, Lee-May, Provencher, Diane, Ma, Ling, Brenton, James D, Castro, Cesar, Green, Michelle, Simmons, Andrew D, Beltman, Jeri, Harding, Thomas, Lin, Kevin K, Goble, Sandra, Maloney, Lara, Kristeleit, Rebecca S, McNeish, Iain A, Swisher, Elizabeth M, and Xiao, Jim J

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Clinical Research, Ovarian Cancer, Orphan Drug, Rare Diseases, Cancer, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Administration, Oral, Aged, Area Under Curve, BRCA1 Protein, Carcinoma, Ovarian Epithelial, Dose-Response Relationship, Drug, Female, Humans, Indoles, Middle Aged, Neoplasm Recurrence, Local, Ovarian Neoplasms, Platinum, Efficacy, Exposure, Ovarian carcinoma, Pharmacokinetics, Rucaparib, Safety, Paediatrics and Reproductive Medicine, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis, Reproductive medicine
Abstract

ObjectiveTo evaluate correlations between rucaparib exposure and selected efficacy and safety endpoints in patients with recurrent ovarian carcinoma using pooled data from Study 10 and ARIEL2.MethodsEfficacy analyses were limited to patients with carcinomas harboring a deleterious BRCA1 or BRCA2 mutation who had received ≥2 prior lines of chemotherapy. Safety was evaluated in all patients who received ≥1 rucaparib dose. Steady-state daily area under the concentration-time curve (AUCss) and maximum concentration (Cmax,ss) for rucaparib were calculated for each patient and averaged by actual dose received over time (AUCavg,ss and Cmax,avg,ss) using a previously developed population pharmacokinetic model.ResultsRucaparib exposure was dose-proportional and not associated with baseline patient weight. In the exposure-efficacy analyses (n = 121), AUCavg,ss was positively associated with independent radiology review-assessed RECIST response in the subgroup of patients with platinum-sensitive recurrent disease (n = 75, p = 0.017). In the exposure-safety analyses (n = 393, 40 mg once daily to 840 mg twice daily [BID] starting doses), most patients received a 600 mg BID rucaparib starting dose, with 27% and 21% receiving 1 or ≥2 dose reductions, respectively. Cmax,ss was significantly correlated with grade ≥2 serum creatinine increase, grade ≥3 alanine transaminase/aspartate transaminase increase, platelet decrease, fatigue/asthenia, and maximal hemoglobin decrease (p

Published
2021

6. Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2).

Author

Swisher, Elizabeth M, Kwan, Tanya T, Oza, Amit M, Tinker, Anna V, Ray-Coquard, Isabelle, Oaknin, Ana, Coleman, Robert L, Aghajanian, Carol, Konecny, Gottfried E, O'Malley, David M, Leary, Alexandra, Provencher, Diane, Welch, Stephen, Chen, Lee-May, Wahner Hendrickson, Andrea E, Ma, Ling, Ghatage, Prafull, Kristeleit, Rebecca S, Dorigo, Oliver, Musafer, Ashan, Kaufmann, Scott H, Elvin, Julia A, Lin, Douglas I, Chambers, Setsuko K, Dominy, Erin, Vo, Lan-Thanh, Goble, Sandra, Maloney, Lara, Giordano, Heidi, Harding, Thomas, Dobrovic, Alexander, Scott, Clare L, Lin, Kevin K, and McNeish, Iain A

Subjects
Humans, Ovarian Neoplasms, Neoplasm Recurrence, Local, Platinum, Indoles, DNA-Binding Proteins, BRCA1 Protein, BRCA2 Protein, Antineoplastic Agents, DNA Methylation, Adult, Aged, Aged, 80 and over, Middle Aged, Female, Promoter Regions, Genetic, Poly(ADP-ribose) Polymerase Inhibitors, Carcinoma, Ovarian Epithelial
Abstract

ARIEL2 (NCT01891344) is a single-arm, open-label phase 2 study of the PARP inhibitor (PARPi) rucaparib in relapsed high-grade ovarian carcinoma. In this post hoc exploratory biomarker analysis of pre- and post-platinum ARIEL2 samples, RAD51C and RAD51D mutations and high-level BRCA1 promoter methylation predict response to rucaparib, similar to BRCA1/BRCA2 mutations. BRCA1 methylation loss may be a major cross-resistance mechanism to platinum and PARPi. Genomic scars associated with homologous recombination deficiency are irreversible, persisting even as platinum resistance develops, and therefore are predictive of rucaparib response only in platinum-sensitive disease. The RAS, AKT, and cell cycle pathways may be additional modulators of PARPi sensitivity.

Published
2021

7. Survival and modelled cancer antigen-125 ELIMination rate constant K score in ovarian cancer patients in first-line before poly(ADP-ribose) polymerase inhibitor era: A Gynaecologic Cancer Intergroup meta-analysis

Author

Corbaux, Pauline, You, Benoit, Glasspool, Rosalind M., Yanaihara, Nozomu, Tinker, Anna V., Lindemann, Kristina, Ray-Coquard, Isabelle L., Mirza, Mansoor R., Subtil, Fabien, Colomban, Olivier, Péron, Julien, Karamouza, Eleni, McNeish, Iain, Kelly, Caroline, Kagimura, Tatsuo, Welch, Stephen, Lewsley, Liz-Anne, Paoletti, Xavier, and Cook, Adrian

Published
2023
Full Text
View/download PDF

8. Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies

Author

Hilton, John, Gelmon, Karen, Bedard, Philippe L., Tu, Dongsheng, Xu, Hong, Tinker, Anna V., Goodwin, Rachel, Laurie, Scott A., Jonker, Derek, Hansen, Aaron R., Veitch, Zachary W., Renouf, Daniel J., Hagerman, Linda, Lui, Hongbo, Chen, Bingshu, Kellar, Deb, Li, Irene, Lee, Sung-Eun, Kono, Takako, Cheng, Brian Y. C., Yap, Damian, Lai, Daniel, Beatty, Sean, Soong, John, Pritchard, Kathleen I., Soria-Bretones, Isabel, Chen, Eric, Feilotter, Harriet, Rushton, Moira, Seymour, Lesley, Aparicio, Samuel, and Cescon, David W.

Published
2022
Full Text
View/download PDF

9. Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study

Author

Pujade-Lauraine, Eric, Fujiwara, Keiichi, Ledermann, Jonathan A, Oza, Amit M, Kristeleit, Rebecca, Ray-Coquard, Isabelle-Laure, Richardson, Gary E, Sessa, Cristiana, Yonemori, Kan, Banerjee, Susana, Leary, Alexandra, Tinker, Anna V, Jung, Kyung Hae, Madry, Radoslaw, Park, Sang-Yoon, Anderson, Charles K, Zohren, Fabian, Stewart, Ross A, Wei, Caimiao, Dychter, Samuel S, and Monk, Bradley J

Published
2021
Full Text
View/download PDF

10. Detection and genomic characterization of a mammary-like adenocarcinoma

Author

Grewal, Jasleen K, Eirew, Peter, Jones, Martin, Chiu, Kenrry, Tessier-Cloutier, Basile, Karnezis, Anthony N, Karsan, Aly, Mungall, Andy, Zhou, Chen, Yip, Stephen, Tinker, Anna V, Laskin, Janessa, Marra, Marco, and Jones, Steven JM

Subjects
Biological Sciences, Biomedical and Clinical Sciences, Genetics, Oncology and Carcinogenesis, Biotechnology, Cancer, Human Genome, Breast Cancer, Prevention, Rare Diseases, Good Health and Well Being, Adenocarcinoma, Breast, Breast Neoplasms, Diagnosis, Differential, Female, Gene Expression Profiling, Genomics, Humans, Immunohistochemistry, Middle Aged, Receptor, ErbB-2, Transcriptome, Vulva, Vulvar Neoplasms, Whole Genome Sequencing, Receptor, erbB-2, neoplasm of the breast, neoplasm of the genitourinary tract, Pharmacology and pharmaceutical sciences
Abstract

Whole-genome and transcriptome sequencing were performed to identify potential therapeutic strategies in the absence of viable treatment options for a patient initially diagnosed with vulvar adenocarcinoma. Genomic events were prioritized by comparison against variant distributions in the TCGA pan-cancer data set and complemented with detailed transcriptome sequencing and copy-number analysis. These findings were considered against published scientific literature in order to evaluate the functional effects of potentially relevant genomic events. Analysis of the transcriptome against a background of 27 TCGA cancer types led to reclassification of the tumor as a primary HER2+ mammary-like adenocarcinoma of the vulva. This revised diagnosis was subsequently confirmed by follow-up immunohistochemistry for a mammary-like adenocarcinoma. The patient was treated with chemotherapy and targeted therapies for HER2+ breast cancer. The detailed pathology and genomic findings of this case are presented herein.

Published
2017

11. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial

Author

Swisher, Elizabeth M, Lin, Kevin K, Oza, Amit M, Scott, Clare L, Giordano, Heidi, Sun, James, Konecny, Gottfried E, Coleman, Robert L, Tinker, Anna V, O'Malley, David M, Kristeleit, Rebecca S, Ma, Ling, Bell-McGuinn, Katherine M, Brenton, James D, Cragun, Janiel M, Oaknin, Ana, Ray-Coquard, Isabelle, Harrell, Maria I, Mann, Elaina, Kaufmann, Scott H, Floquet, Anne, Leary, Alexandra, Harding, Thomas C, Goble, Sandra, Maloney, Lara, Isaacson, Jeff, Allen, Andrew R, Rolfe, Lindsey, Yelensky, Roman, Raponi, Mitch, and McNeish, Iain A

Subjects
Rare Diseases, Genetics, Cancer, Ovarian Cancer, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, 5.1 Pharmaceuticals, Development of treatments and therapeutic interventions, Good Health and Well Being, Aged, Antineoplastic Agents, BRCA1 Protein, BRCA2 Protein, Carcinoma, Ovarian Epithelial, Drug Resistance, Neoplasm, Fallopian Tube Neoplasms, Female, Follow-Up Studies, Germ-Line Mutation, Humans, Indoles, International Agencies, Middle Aged, Neoplasm Recurrence, Local, Neoplasm Staging, Neoplasms, Glandular and Epithelial, Ovarian Neoplasms, Peritoneal Neoplasms, Platinum, Poly(ADP-ribose) Polymerase Inhibitors, Poly(ADP-ribose) Polymerases, Prognosis, Prospective Studies, Salvage Therapy, Survival Rate, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

BackgroundPoly(ADP-ribose) polymerase (PARP) inhibitors have activity in ovarian carcinomas with homologous recombination deficiency. Along with BRCA1 and BRCA2 (BRCA) mutations genomic loss of heterozygosity (LOH) might also represent homologous recombination deficiency. In ARIEL2, we assessed the ability of tumour genomic LOH, quantified with a next-generation sequencing assay, to predict response to rucaparib, an oral PARP inhibitor.MethodsARIEL2 is an international, multicentre, two-part, phase 2, open-label study done at 49 hospitals and cancer centres in Australia, Canada, France, Spain, the UK, and the USA. In ARIEL2 Part 1, patients with recurrent, platinum-sensitive, high-grade ovarian carcinoma were classified into one of three predefined homologous recombination deficiency subgroups on the basis of tumour mutational analysis: BRCA mutant (deleterious germline or somatic), BRCA wild-type and LOH high (LOH high group), or BRCA wild-type and LOH low (LOH low group). We prespecified a cutoff of 14% or more genomic LOH for LOH high. Patients began treatment with oral rucaparib at 600 mg twice per day for continuous 28 day cycles until disease progression or any other reason for discontinuation. The primary endpoint was progression-free survival. All patients treated with at least one dose of rucaparib were included in the safety analyses and all treated patients who were classified were included in the primary endpoint analysis. This trial is registered with ClinicalTrials.gov, number NCT01891344. Enrolment into ARIEL2 Part 1 is complete, although an extension (Part 2) is ongoing.Findings256 patients were screened and 206 were enrolled between Oct 30, 2013, and Dec 19, 2014. At the data cutoff date (Jan 18, 2016), 204 patients had received rucaparib, with 28 patients remaining in the study. 192 patients could be classified into one of the three predefined homologous recombination deficiency subgroups: BRCA mutant (n=40), LOH high (n=82), or LOH low (n=70). Tumours from 12 patients were established as BRCA wild-type, but could not be classified for LOH, because of insufficient neoplastic nuclei in the sample. The median duration of treatment for the 204 patients was 5·7 months (IQR 2·8-10·1). 24 patients in the BRCA mutant subgroup, 56 patients in the LOH high subgroup, and 59 patients in the LOH low subgroup had disease progression or died. Median progression-free survival after rucaparib treatment was 12·8 months (95% CI 9·0-14·7) in the BRCA mutant subgroup, 5·7 months (5·3-7·6) in the LOH high subgroup, and 5·2 months (3·6-5·5) in the LOH low subgroup. Progression-free survival was significantly longer in the BRCA mutant (hazard ratio 0·27, 95% CI 0·16-0·44, p

Published
2017

12. Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer

Author

Swisher, Elizabeth M., Kristeleit, Rebecca S., Oza, Amit M., Tinker, Anna V., Ray-Coquard, Isabelle, Oaknin, Ana, Coleman, Robert L., Burris, Howard A., Aghajanian, Carol, O'Malley, David M., Leary, Alexandra, Welch, Stephen, Provencher, Diane, Shapiro, Geoffrey I., Chen, Lee-may, Shapira-Frommer, Ronnie, Kaufmann, Scott H., Goble, Sandra, Maloney, Lara, Kwan, Tanya, Lin, Kevin K., and McNeish, Iain A.

Published
2021
Full Text
View/download PDF

13. Low-grade serous carcinoma (LGSC): A Canadian multicenter review of practice patterns and patient outcomes

Author

Scott, Stephanie A., Llaurado Fernandez, Marta, Kim, Hannah, Elit, Laurie, Nourmoussavi, Melica, Glaze, Sarah, Roberts, Lesley, Offman, Saul L., Rahimi, Kurosh, Lytwyn, Alice, Sur, Monalisa, Gilks, C. Blake, Matheson, Kara, Köbel, Martin, Dawson, Amy, Tinker, Anna V., Kwon, Janice S., Hoskins, Paul, Santos, Jennifer L., Cheung, Andrea, Provencher, Diane, and Carey, Mark S.

Published
2020
Full Text
View/download PDF

15. Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data

Author

Aggarwal, Simi, Bronger, Holger, Brown, Elizabeth B., Buck, Martin, Bukhari, Syed A., Coghlan, Edwina, Cope, Nichola, de Almeida, Michelle Samora, De Kroon, Cornelius D., Dean, Andrew, Devlin, Michael-John, Ditzel, Helena M., Drecoll, Enken, Ebata, Takahiro, Fagotti, Anna, Faruqi, Asma, Feeney, Laura, Gupta, Kavita, Harley, Ian, Inzani, Frediano, Jeyarajah, Arjun R., Koay, M.H. Eleanor, Kroep, Judith R., Lee, Jung-Yun, Leung, Yee, Lockley, Michelle, Loft, Alice R., MaGee, Daniel, Manchanda, Ranjit, McKenna, Sarah, Midha, Divya, Millan, David, Millar, Joanne, Miller, Rowan, Mohan, Ganendra R., Mughal, Sohail, Mukhopadhyay, Asima, Nicolau, Sergio Mancini, Nevin, James, Oakley, Abigail S., Quigley, Mary, Rai, Bhavana, Rajwanshi, Arvind, Salfinger, Stuart G., Scambia, Giovanni, Scatchard, Kate, Schmalfeldt, Barbara, Simcock, Bryony, Singh, Priya, Strickland, Kyle C., Suri, Vainta, Syed, Sheeba, Sykes, Peter, Tamura, Kenji, Tan, Adeline, Tan, Jason, Thompson, Emily, Tinker, Anna V., Trevisan, Georgia, Uyeda, Maria Gabriela Baumgarten Kuster, Vaughan, Michelle M., Weichert, Wilko, Williams, Anthony, Williams, Sarah, Yoshida, Hiroshi, Zorzato, Pier Carlo, Cohen, Paul A., Powell, Aime, Böhm, Steffen, Gilks, C. Blake, Stewart, Colin J.R., Meniawy, Tarek M., Bulsara, Max, Avril, Stefanie, Brockbank, Eleanor C., Bosse, Tjalling, de Azevedo Focchi, Gustavo Rubino, Ganesan, Raji, Glasspool, Rosalind M., Howitt, Brooke E., Kim, Hyun-Soo, Le, Nhu D., Mandalia, Trupti, McCluggage, W. Glenn, McNeish, Iain, Srinivasan, Radhika, Tan, Yun Yi, van der Griend, Rachael, Yunokawa, Mayu, Zannoni, Gian F., and Singh, Naveena

Published
2019
Full Text
View/download PDF

16. Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial

Author

Fabbro, Michel, Moore, Kathleen N., Dørum, Anne, Tinker, Anna V., Mahner, Sven, Bover, Isabel, Banerjee, Susana, Tognon, Germana, Goffin, Frederic, Shapira-Frommer, Ronnie, Wenham, Robert M., Hellman, Kristina, Provencher, Diane, Harter, Philipp, Vázquez, Isabel Palacio, Follana, Philippe, Pineda, Mario J., Mirza, Mansoor R., Hazard, Sebastien J., and Matulonis, Ursula A.

Published
2019
Full Text
View/download PDF

18. Supplementary Appendix 1 from Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study

Author

Oaknin, Ana, primary, Pothuri, Bhavana, primary, Gilbert, Lucy, primary, Sabatier, Renaud, primary, Brown, Jubilee, primary, Ghamande, Sharad, primary, Mathews, Cara, primary, O'Malley, David M., primary, Kristeleit, Rebecca, primary, Boni, Valentina, primary, Gravina, Adriano, primary, Banerjee, Susana, primary, Miller, Rowan, primary, Pikiel, Joanna, primary, Mirza, Mansoor R., primary, Dewal, Ninad, primary, Antony, Grace, primary, Dong, Yuping, primary, Zografos, Eleftherios, primary, Veneris, Jennifer, primary, and Tinker, Anna V., primary

Published
2023
Full Text
View/download PDF

19. Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid Tumors

Author

André, Thierry, primary, Berton, Dominique, additional, Curigliano, Giuseppe, additional, Sabatier, Renaud, additional, Tinker, Anna V., additional, Oaknin, Ana, additional, Ellard, Susan, additional, de Braud, Filippo, additional, Arkenau, Hendrik-Tobias, additional, Trigo, José, additional, Gravina, Adriano, additional, Kristeleit, Rebecca, additional, Moreno, Victor, additional, Abdeddaim, Cyril, additional, Vano, Yann-Alexandre, additional, Samouëlian, Vanessa, additional, Miller, Rowan, additional, Boni, Valentina, additional, Torres, Antonio Antón, additional, Gilbert, Lucy, additional, Brown, Jubilee, additional, Dewal, Ninad, additional, Dabrowski, Christine, additional, Antony, Grace, additional, Zografos, Eleftherios, additional, Veneris, Jennifer, additional, and Banerjee, Susana, additional

Published
2023
Full Text
View/download PDF

20. #161 Final overall survival and long-term safety in the ENGOT-OV16/NOVA phase 3 trial of niraparib in patients with recurrent ovarian cancer

Author

Mirza, Mansoor R, primary, Herrstedt, Jørn, additional, Oza, Amit, additional, Mahner, Sven, additional, Redondo, Andrés, additional, Berton, Dominique, additional, Berek, Jonathan S, additional, Haslund, Charlotte A, additional, Marmé, Frederik, additional, González-Martín, Antonio, additional, Becourt, Stéphanie, additional, Tinker, Anna V, additional, Ledermann, Jonathan, additional, Benigno, Benedict, additional, Lindahl, Gabriel, additional, Colombo, Nicoletta, additional, Malinowska, Izabela A, additional, Liu, Wenlei, additional, Monk, Bradley J, additional, and Matulonis, Ursula, additional

Published
2023
Full Text
View/download PDF

21. #163 Results from a phase I/II trial of tinostamustine monotherapy in advanced solid tumours (NCT03345485): safety and efficacy in a subset of patients with advanced ovarian cancer (OvCa)

Author

Tinker, Anna V, primary, Chugh, Rashmi, additional, Curigliano, Giuseppe, additional, Kummar, Shivaani, additional, Schneider, Reva, additional, Strauss, James, additional, Janik, Tomas, additional, Manamley, Nick, additional, Hilgier, Kasia, additional, and Oaknin, Ana, additional

Published
2023
Full Text
View/download PDF

24. A plain language summary of results from the GARNET study of dostarlimab in patients with endometrial cancer

Author

Oaknin, Ana, primary, Gilbert, Lucy, additional, Tinker, Anna V, additional, Brown, Jubilee, additional, Mathews, Cara, additional, Press, Joshua, additional, Sabatier, Renaud, additional, O'Malley, David M, additional, Samouelian, Vanessa, additional, Boni, Valentina, additional, Duska, Linda, additional, Ghamande, Sharad, additional, Ghatage, Prafull, additional, Kristeleit, Rebecca, additional, Leath, Charles, additional, Dong, Yuping, additional, Veneris, Jennifer, additional, and Pothuri, Bhavana, additional

Published
2023
Full Text
View/download PDF

25. Data from Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study

Author

Oaknin, Ana, primary, Pothuri, Bhavana, primary, Gilbert, Lucy, primary, Sabatier, Renaud, primary, Brown, Jubilee, primary, Ghamande, Sharad, primary, Mathews, Cara, primary, O'Malley, David M., primary, Kristeleit, Rebecca, primary, Boni, Valentina, primary, Gravina, Adriano, primary, Banerjee, Susana, primary, Miller, Rowan, primary, Pikiel, Joanna, primary, Mirza, Mansoor R., primary, Dewal, Ninad, primary, Antony, Grace, primary, Dong, Yuping, primary, Zografos, Eleftherios, primary, Veneris, Jennifer, primary, and Tinker, Anna V., primary

Published
2023
Full Text
View/download PDF

26. Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study

Author

Oaknin, Ana, primary, Pothuri, Bhavana, additional, Gilbert, Lucy, additional, Sabatier, Renaud, additional, Brown, Jubilee, additional, Ghamande, Sharad, additional, Mathews, Cara, additional, O'Malley, David M., additional, Kristeleit, Rebecca, additional, Boni, Valentina, additional, Gravina, Adriano, additional, Banerjee, Susana, additional, Miller, Rowan, additional, Pikiel, Joanna, additional, Mirza, Mansoor R., additional, Dewal, Ninad, additional, Antony, Grace, additional, Dong, Yuping, additional, Zografos, Eleftherios, additional, Veneris, Jennifer, additional, and Tinker, Anna V., additional

Published
2023
Full Text
View/download PDF

27. Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2

Author

Oza, Amit M., Tinker, Anna V., Oaknin, Ana, Shapira-Frommer, Ronnie, McNeish, Iain A., Swisher, Elizabeth M., Ray-Coquard, Isabelle, Bell-McGuinn, Katherine, Coleman, Robert L., O'Malley, David M., Leary, Alexandra, Chen, Lee-may, Provencher, Diane, Ma, Ling, Brenton, James D., Konecny, Gottfried E., Castro, Cesar M., Giordano, Heidi, Maloney, Lara, Goble, Sandra, Lin, Kevin K., Sun, James, Raponi, Mitch, Rolfe, Lindsey, and Kristeleit, Rebecca S.

Published
2017
Full Text
View/download PDF

28. Data from Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma

Author

Kondrashova, Olga, primary, Nguyen, Minh, primary, Shield-Artin, Kristy, primary, Tinker, Anna V., primary, Teng, Nelson N.H., primary, Harrell, Maria I., primary, Kuiper, Michael J., primary, Ho, Gwo-Yaw, primary, Barker, Holly, primary, Jasin, Maria, primary, Prakash, Rohit, primary, Kass, Elizabeth M., primary, Sullivan, Meghan R., primary, Brunette, Gregory J., primary, Bernstein, Kara A., primary, Coleman, Robert L., primary, Floquet, Anne, primary, Friedlander, Michael, primary, Kichenadasse, Ganessan, primary, O'Malley, David M., primary, Oza, Amit, primary, Sun, James, primary, Robillard, Liliane, primary, Maloney, Lara, primary, Bowtell, David, primary, Giordano, Heidi, primary, Wakefield, Matthew J., primary, Kaufmann, Scott H., primary, Simmons, Andrew D., primary, Harding, Thomas C., primary, Raponi, Mitch, primary, McNeish, Iain A., primary, Swisher, Elizabeth M., primary, Lin, Kevin K., primary, and Scott, Clare L., primary

Published
2023
Full Text
View/download PDF

29. Data from Mutation of ERBB2 Provides a Novel Alternative Mechanism for the Ubiquitous Activation of RAS-MAPK in Ovarian Serous Low Malignant Potential Tumors

Author

Anglesio, Michael S., primary, Arnold, Jeremy M., primary, George, Joshy, primary, Tinker, Anna V., primary, Tothill, Richard, primary, Waddell, Nic, primary, Simms, Lisa, primary, Locandro, Bianca, primary, Fereday, Sian, primary, Traficante, Nadia, primary, Russell, Peter, primary, Sharma, Raghwa, primary, Birrer, Michael J., primary, deFazio, Anna, primary, Chenevix-Trench, Georgia, primary, and Bowtell, David D.L., primary

Published
2023
Full Text
View/download PDF

30. Table S2 from BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma

Author

Lin, Kevin K., primary, Harrell, Maria I., primary, Oza, Amit M., primary, Oaknin, Ana, primary, Ray-Coquard, Isabelle, primary, Tinker, Anna V., primary, Helman, Elena, primary, Radke, Marc R., primary, Say, Carmen, primary, Vo, Lan-Thanh, primary, Mann, Elaina, primary, Isaacson, Jeffrey D., primary, Maloney, Lara, primary, O'Malley, David M., primary, Chambers, Setsuko K., primary, Kaufmann, Scott H., primary, Scott, Clare L., primary, Konecny, Gottfried E., primary, Coleman, Robert L., primary, Sun, James X., primary, Giordano, Heidi, primary, Brenton, James D., primary, Harding, Thomas C., primary, McNeish, Iain A., primary, and Swisher, Elizabeth M., primary

Published
2023
Full Text
View/download PDF

31. Supplementary Tables and Supplementary Figures 1 through 11 from Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma

Author

Kondrashova, Olga, primary, Nguyen, Minh, primary, Shield-Artin, Kristy, primary, Tinker, Anna V., primary, Teng, Nelson N.H., primary, Harrell, Maria I., primary, Kuiper, Michael J., primary, Ho, Gwo-Yaw, primary, Barker, Holly, primary, Jasin, Maria, primary, Prakash, Rohit, primary, Kass, Elizabeth M., primary, Sullivan, Meghan R., primary, Brunette, Gregory J., primary, Bernstein, Kara A., primary, Coleman, Robert L., primary, Floquet, Anne, primary, Friedlander, Michael, primary, Kichenadasse, Ganessan, primary, O'Malley, David M., primary, Oza, Amit, primary, Sun, James, primary, Robillard, Liliane, primary, Maloney, Lara, primary, Bowtell, David, primary, Giordano, Heidi, primary, Wakefield, Matthew J., primary, Kaufmann, Scott H., primary, Simmons, Andrew D., primary, Harding, Thomas C., primary, Raponi, Mitch, primary, McNeish, Iain A., primary, Swisher, Elizabeth M., primary, Lin, Kevin K., primary, and Scott, Clare L., primary

Published
2023
Full Text
View/download PDF

32. Supp Table 1 from Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma

Author

Kondrashova, Olga, primary, Nguyen, Minh, primary, Shield-Artin, Kristy, primary, Tinker, Anna V., primary, Teng, Nelson N.H., primary, Harrell, Maria I., primary, Kuiper, Michael J., primary, Ho, Gwo-Yaw, primary, Barker, Holly, primary, Jasin, Maria, primary, Prakash, Rohit, primary, Kass, Elizabeth M., primary, Sullivan, Meghan R., primary, Brunette, Gregory J., primary, Bernstein, Kara A., primary, Coleman, Robert L., primary, Floquet, Anne, primary, Friedlander, Michael, primary, Kichenadasse, Ganessan, primary, O'Malley, David M., primary, Oza, Amit, primary, Sun, James, primary, Robillard, Liliane, primary, Maloney, Lara, primary, Bowtell, David, primary, Giordano, Heidi, primary, Wakefield, Matthew J., primary, Kaufmann, Scott H., primary, Simmons, Andrew D., primary, Harding, Thomas C., primary, Raponi, Mitch, primary, McNeish, Iain A., primary, Swisher, Elizabeth M., primary, Lin, Kevin K., primary, and Scott, Clare L., primary

Published
2023
Full Text
View/download PDF

33. Supplementary Data from Mutation of ERBB2 Provides a Novel Alternative Mechanism for the Ubiquitous Activation of RAS-MAPK in Ovarian Serous Low Malignant Potential Tumors

Author

Anglesio, Michael S., primary, Arnold, Jeremy M., primary, George, Joshy, primary, Tinker, Anna V., primary, Tothill, Richard, primary, Waddell, Nic, primary, Simms, Lisa, primary, Locandro, Bianca, primary, Fereday, Sian, primary, Traficante, Nadia, primary, Russell, Peter, primary, Sharma, Raghwa, primary, Birrer, Michael J., primary, deFazio, Anna, primary, Chenevix-Trench, Georgia, primary, and Bowtell, David D.L., primary

Published
2023
Full Text
View/download PDF

34. Supp Table 4 from Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma

Author

Kondrashova, Olga, primary, Nguyen, Minh, primary, Shield-Artin, Kristy, primary, Tinker, Anna V., primary, Teng, Nelson N.H., primary, Harrell, Maria I., primary, Kuiper, Michael J., primary, Ho, Gwo-Yaw, primary, Barker, Holly, primary, Jasin, Maria, primary, Prakash, Rohit, primary, Kass, Elizabeth M., primary, Sullivan, Meghan R., primary, Brunette, Gregory J., primary, Bernstein, Kara A., primary, Coleman, Robert L., primary, Floquet, Anne, primary, Friedlander, Michael, primary, Kichenadasse, Ganessan, primary, O'Malley, David M., primary, Oza, Amit, primary, Sun, James, primary, Robillard, Liliane, primary, Maloney, Lara, primary, Bowtell, David, primary, Giordano, Heidi, primary, Wakefield, Matthew J., primary, Kaufmann, Scott H., primary, Simmons, Andrew D., primary, Harding, Thomas C., primary, Raponi, Mitch, primary, McNeish, Iain A., primary, Swisher, Elizabeth M., primary, Lin, Kevin K., primary, and Scott, Clare L., primary

Published
2023
Full Text
View/download PDF

35. Figures S1-S8 from BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma

Author

Lin, Kevin K., primary, Harrell, Maria I., primary, Oza, Amit M., primary, Oaknin, Ana, primary, Ray-Coquard, Isabelle, primary, Tinker, Anna V., primary, Helman, Elena, primary, Radke, Marc R., primary, Say, Carmen, primary, Vo, Lan-Thanh, primary, Mann, Elaina, primary, Isaacson, Jeffrey D., primary, Maloney, Lara, primary, O'Malley, David M., primary, Chambers, Setsuko K., primary, Kaufmann, Scott H., primary, Scott, Clare L., primary, Konecny, Gottfried E., primary, Coleman, Robert L., primary, Sun, James X., primary, Giordano, Heidi, primary, Brenton, James D., primary, Harding, Thomas C., primary, McNeish, Iain A., primary, and Swisher, Elizabeth M., primary

Published
2023
Full Text
View/download PDF

36. Supp Video from Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma

Author

Kondrashova, Olga, primary, Nguyen, Minh, primary, Shield-Artin, Kristy, primary, Tinker, Anna V., primary, Teng, Nelson N.H., primary, Harrell, Maria I., primary, Kuiper, Michael J., primary, Ho, Gwo-Yaw, primary, Barker, Holly, primary, Jasin, Maria, primary, Prakash, Rohit, primary, Kass, Elizabeth M., primary, Sullivan, Meghan R., primary, Brunette, Gregory J., primary, Bernstein, Kara A., primary, Coleman, Robert L., primary, Floquet, Anne, primary, Friedlander, Michael, primary, Kichenadasse, Ganessan, primary, O'Malley, David M., primary, Oza, Amit, primary, Sun, James, primary, Robillard, Liliane, primary, Maloney, Lara, primary, Bowtell, David, primary, Giordano, Heidi, primary, Wakefield, Matthew J., primary, Kaufmann, Scott H., primary, Simmons, Andrew D., primary, Harding, Thomas C., primary, Raponi, Mitch, primary, McNeish, Iain A., primary, Swisher, Elizabeth M., primary, Lin, Kevin K., primary, and Scott, Clare L., primary

Published
2023
Full Text
View/download PDF

37. Supplementary Data from Integrated Genome-Wide DNA Copy Number and Expression Analysis Identifies Distinct Mechanisms of Primary Chemoresistance in Ovarian Carcinomas

Author

Etemadmoghadam, Dariush, primary, deFazio, Anna, primary, Beroukhim, Rameen, primary, Mermel, Craig, primary, George, Joshy, primary, Getz, Gad, primary, Tothill, Richard, primary, Okamoto, Aikou, primary, Raeder, Maria B., primary, Harnett, Paul, primary, Lade, Stephen, primary, Akslen, Lars A., primary, Tinker, Anna V., primary, Locandro, Bianca, primary, Alsop, Kathryn, primary, Chiew, Yoke-Eng, primary, Traficante, Nadia, primary, Fereday, Sian, primary, Johnson, Daryl, primary, Fox, Stephen, primary, Sellers, William, primary, Urashima, Mitsuyoshi, primary, Salvesen, Helga B., primary, Meyerson, Matthew, primary, and Bowtell, David, primary

Published
2023
Full Text
View/download PDF

38. Supplementary Data from Endometrial Cancer Molecular Risk Stratification is Equally Prognostic for Endometrioid Ovarian Carcinoma

Author

Krämer, Pauline, primary, Talhouk, Aline, primary, Brett, Mary Anne, primary, Chiu, Derek S., primary, Cairns, Evan S., primary, Scheunhage, Daniëlla A., primary, Hammond, Rory F.L., primary, Farnell, David, primary, Nazeran, Tayyebeh M., primary, Grube, Marcel, primary, Xia, Zhouchunyang, primary, Senz, Janine, primary, Leung, Samuel, primary, Feil, Lukas, primary, Pasternak, Jana, primary, Dixon, Katherine, primary, Hartkopf, Andreas, primary, Krämer, Bernhard, primary, Brucker, Sara, primary, Heitz, Florian, primary, du Bois, Andreas, primary, Harter, Philipp, primary, Kommoss, Felix K.F., primary, Sinn, Hans-Peter, primary, Heublein, Sabine, primary, Kommoss, Friedrich, primary, Vollert, Hans-Walter, primary, Manchanda, Ranjit, primary, de Kroon, Cornelis D., primary, Nijman, Hans W., primary, de Bruyn, Marco, primary, Thompson, Emily F., primary, Bashashati, Ali, primary, McAlpine, Jessica N., primary, Singh, Naveena, primary, Tinker, Anna V., primary, Staebler, Annette, primary, Bosse, Tjalling, primary, Kommoss, Stefan, primary, Köbel, Martin, primary, and Anglesio, Michael S., primary

Published
2023
Full Text
View/download PDF

39. Table S 1-6 and Figures S1-3 from Dose-Ranging and Cohort-Expansion Study of Monalizumab (IPH2201) in Patients with Advanced Gynecologic Malignancies: A Trial of the Canadian Cancer Trials Group (CCTG): IND221

Author

Tinker, Anna V., primary, Hirte, Holger W., primary, Provencher, Diane, primary, Butler, Marcus, primary, Ritter, Heather, primary, Tu, Dongsheng, primary, Azim, Hatem A., primary, Paralejas, Paulo, primary, Grenier, Nathalie, primary, Hahn, Shirley-Ann, primary, Ramsahai, Janelle, primary, and Seymour, Lesley, primary

Published
2023
Full Text
View/download PDF

40. Data from Integrated Genome-Wide DNA Copy Number and Expression Analysis Identifies Distinct Mechanisms of Primary Chemoresistance in Ovarian Carcinomas

Author

Etemadmoghadam, Dariush, primary, deFazio, Anna, primary, Beroukhim, Rameen, primary, Mermel, Craig, primary, George, Joshy, primary, Getz, Gad, primary, Tothill, Richard, primary, Okamoto, Aikou, primary, Raeder, Maria B., primary, Harnett, Paul, primary, Lade, Stephen, primary, Akslen, Lars A., primary, Tinker, Anna V., primary, Locandro, Bianca, primary, Alsop, Kathryn, primary, Chiew, Yoke-Eng, primary, Traficante, Nadia, primary, Fereday, Sian, primary, Johnson, Daryl, primary, Fox, Stephen, primary, Sellers, William, primary, Urashima, Mitsuyoshi, primary, Salvesen, Helga B., primary, Meyerson, Matthew, primary, and Bowtell, David, primary

Published
2023
Full Text
View/download PDF

41. Supplementary Data from Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome

Author

Tothill, Richard W., primary, Tinker, Anna V., primary, George, Joshy, primary, Brown, Robert, primary, Fox, Stephen B., primary, Lade, Stephen, primary, Johnson, Daryl S., primary, Trivett, Melanie K., primary, Etemadmoghadam, Dariush, primary, Locandro, Bianca, primary, Traficante, Nadia, primary, Fereday, Sian, primary, Hung, Jillian A., primary, Chiew, Yoke-Eng, primary, Haviv, Izhak, primary, Gertig, Dorota, primary, deFazio, Anna, primary, and Bowtell, David D.L., primary

Published
2023
Full Text
View/download PDF

45. sj-docx-1-tam-10.1177_17588359231157633 – Supplemental material for A rapidly evolving landscape: immune checkpoint inhibitors in pretreated metastatic endometrial cancer

Author

Tinker, Anna V., Dhani, Neesha C., Ghatage, Prafull, McLeod, Deanna, Samouëlian, Vanessa, Welch, Stephen A., and Altman, Alon D.

Subjects
110203 Respiratory Diseases, FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, sj-docx-1-tam-10.1177_17588359231157633 for A rapidly evolving landscape: immune checkpoint inhibitors in pretreated metastatic endometrial cancer by Anna V. Tinker, Neesha C. Dhani, Prafull Ghatage, Deanna McLeod, Vanessa Samouëlian, Stephen A. Welch and Alon D. Altman in Therapeutic Advances in Medical Oncology

Published
2023
Full Text
View/download PDF

46. Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer

Author

Phelan, Catherine M, Kuchenbaecker, Karoline B, Tyrer, Jonathan P, Kar, Siddhartha P, Lawrenson, Kate, Winham, Stacey J, Dennis, Joe, Pirie, Ailith, Riggan, Marjorie J, Chornokur, Ganna, Earp, Madalene A, Lyra, Jr, Paulo C, Lee, Janet M, Coetzee, Simon, Beesley, Jonathan, McGuffog, Lesley, Soucy, Penny, Dicks, Ed, Lee, Andrew, Barrowdale, Daniel, Lecarpentier, Julie, Leslie, Goska, Aalfs, Cora M, Aben, Katja K H, Adams, Marcia, Adlard, Julian, Andrulis, Irene L, Anton-Culver, Hoda, Antonenkova, Natalia, Aravantinos, Gerasimos, Arnold, Norbert, Arun, Banu K, Arver, Brita, Azzollini, Jacopo, Balmaña, Judith, Banerjee, Susana N, Barjhoux, Laure, Barkardottir, Rosa B, Bean, Yukie, Beckmann, Matthias W, Beeghly-Fadiel, Alicia, Benitez, Javier, Bermisheva, Marina, Bernardini, Marcus Q, Birrer, Michael J, Bjorge, Line, Black, Amanda, Blankstein, Kenneth, Blok, Marinus J, Bodelon, Clara, Bogdanova, Natalia, Bojesen, Anders, Bonanni, Bernardo, Borg, Åke, Bradbury, Angela R, Brenton, James D, Brewer, Carole, Brinton, Louise, Broberg, Per, Brooks-Wilson, Angela, Bruinsma, Fiona, Brunet, Joan, Buecher, Bruno, Butzow, Ralf, Buys, Saundra S, Caldes, Trinidad, Caligo, Maria A, Campbell, Ian, Cannioto, Rikki, Carney, Michael E, Cescon, Terence, Chan, Salina B, Chang-Claude, Jenny, Chanock, Stephen, Chen, Xiao Qing, Chiew, Yoke-Eng, Chiquette, Jocelyne, Chung, Wendy K, Claes, Kathleen B M, Conner, Thomas, Cook, Linda S, Cook, Jackie, Cramer, Daniel W, Cunningham, Julie M, D'Aloisio, Aimee A, Daly, Mary B, Damiola, Francesca, Damirovna, Sakaeva Dina, Dansonka-Mieszkowska, Agnieszka, Dao, Fanny, Davidson, Rosemarie, DeFazio, Anna, Delnatte, Capucine, Doheny, Kimberly F, Diez, Orland, Ding, Yuan Chun, Doherty, Jennifer Anne, Domchek, Susan M, Dorfling, Cecilia M, Dörk, Thilo, Dossus, Laure, Duran, Mercedes, Dürst, Matthias, Dworniczak, Bernd, Eccles, Diana, Edwards, Todd, Eeles, Ros, Eilber, Ursula, Ejlertsen, Bent, Ekici, Arif B, Ellis, Steve, Elvira, Mingajeva, Eng, Kevin H, Engel, Christoph, Evans, D Gareth, Fasching, Peter A, Ferguson, Sarah, Ferrer, Sandra Fert, Flanagan, James M, Fogarty, Zachary C, Fortner, Renée T, Fostira, Florentia, Foulkes, William D, Fountzilas, George, Fridley, Brooke L, Friebel, Tara M, Friedman, Eitan, Frost, Debra, Ganz, Patricia A, Garber, Judy, García, María J, Garcia-Barberan, Vanesa, Gehrig, Andrea, Gentry-Maharaj, Aleksandra, Gerdes, Anne-Marie, Giles, Graham G, Glasspool, Rosalind, Glendon, Gord, Godwin, Andrew K, Goldgar, David E, Goranova, Teodora, Gore, Martin, Greene, Mark H, Gronwald, Jacek, Gruber, Stephen, Hahnen, Eric, Haiman, Christopher A, Håkansson, Niclas, Hamann, Ute, Hansen, Thomas V O, Harrington, Patricia A, Harris, Holly R, Hauke, Jan, Hein, Alexander, Henderson, Alex, Hildebrandt, Michelle A T, Hillemanns, Peter, Hodgson, Shirley, Høgdall, Claus K, Høgdall, Estrid, Hogervorst, Frans B L, Holland, Helene, Hooning, Maartje J, Hosking, Karen, Huang, Ruea-Yea, Hulick, Peter J, Hung, Jillian, Hunter, David J, Huntsman, David G, Huzarski, Tomasz, Imyanitov, Evgeny N, Isaacs, Claudine, Iversen, Edwin S, Izatt, Louise, Izquierdo, Angel, Jakubowska, Anna, James, Paul, Janavicius, Ramunas, Jernetz, Mats, Jensen, Allan, Jensen, Uffe Birk, John, Esther M, Johnatty, Sharon, Jones, Michael E, Kannisto, Päivi, Karlan, Beth Y, Karnezis, Anthony, Kast, Karin, Kennedy, Catherine J, Khusnutdinova, Elza, Kiemeney, Lambertus A, Kiiski, Johanna I, Kim, Sung-Won, Kjaer, Susanne K, Köbel, Martin, Kopperud, Reidun K, Kruse, Torben A, Kupryjanczyk, Jolanta, Kwong, Ava, Laitman, Yael, Lambrechts, Diether, Larrañaga, Nerea, Larson, Melissa C, Lazaro, Conxi, Le, Nhu D, Le Marchand, Loic, Lee, Jong Won, Lele, Shashikant B, Leminen, Arto, Leroux, Dominique, Lester, Jenny, Lesueur, Fabienne, Levine, Douglas A, Liang, Dong, Liebrich, Clemens, Lilyquist, Jenna, Lipworth, Loren, Lissowska, Jolanta, Lu, Karen H, Lubinński, Jan, Luccarini, Craig, Lundvall, Lene, Mai, Phuong L, Mendoza-Fandiño, Gustavo, Manoukian, Siranoush, Massuger, Leon F A G, May, Taymaa, Mazoyer, Sylvie, McAlpine, Jessica N, McGuire, Valerie, McLaughlin, John R, McNeish, Iain, Meijers-Heijboer, Hanne, Meindl, Alfons, Menon, Usha, Mensenkamp, Arjen R, Merritt, Melissa A, Milne, Roger L, Mitchell, Gillian, Modugno, Francesmary, Moes-Sosnowska, Joanna, Moffitt, Melissa, Montagna, Marco, Moysich, Kirsten B, Mulligan, Anna Marie, Musinsky, Jacob, Nathanson, Katherine L, Nedergaard, Lotte, Ness, Roberta B, Neuhausen, Susan L, Nevanlinna, Heli, Niederacher, Dieter, Nussbaum, Robert L, Odunsi, Kunle, Olah, Edith, Olopade, Olufunmilayo I, Olsson, Håkan, Olswold, Curtis, O'Malley, David M, Ong, Kai-ren, Onland-Moret, N Charlotte, Orr, Nicholas, Orsulic, Sandra, Osorio, Ana, Palli, Domenico, Papi, Laura, Park-Simon, Tjoung-Won, Paul, James, Pearce, Celeste L, Pedersen, Inge Søkilde, Peeters, Petra H M, Peissel, Bernard, Peixoto, Ana, Pejovic, Tanja, Pelttari, Liisa M, Permuth, Jennifer B, Peterlongo, Paolo, Pezzani, Lidia, Pfeiler, Georg, Phillips, Kelly-Anne, Piedmonte, Marion, Pike, Malcolm C, Piskorz, Anna M, Poblete, Samantha R, Pocza, Timea, Poole, Elizabeth M, Poppe, Bruce, Porteous, Mary E, Prieur, Fabienne, Prokofyeva, Darya, Pugh, Elizabeth, Pujana, Miquel Angel, Pujol, Pascal, Radice, Paolo, Rantala, Johanna, Rappaport-Fuerhauser, Christine, Rennert, Gad, Rhiem, Kerstin, Rice, Patricia, Richardson, Andrea, Robson, Mark, Rodriguez, Gustavo C, Rodríguez-Antona, Cristina, Romm, Jane, Rookus, Matti A, Rossing, Mary Anne, Rothstein, Joseph H, Rudolph, Anja, Runnebaum, Ingo B, Salvesen, Helga B, Sandler, Dale P, Schoemaker, Minouk J, Senter, Leigha, Setiawan, V Wendy, Severi, Gianluca, Sharma, Priyanka, Shelford, Tameka, Siddiqui, Nadeem, Side, Lucy E, Sieh, Weiva, Singer, Christian F, Sobol, Hagay, Song, Honglin, Southey, Melissa C, Spurdle, Amanda B, Stadler, Zsofia, Steinemann, Doris, Stoppa-Lyonnet, Dominique, Sucheston-Campbell, Lara E, Sukiennicki, Grzegorz, Sutphen, Rebecca, Sutter, Christian, Swerdlow, Anthony J, Szabo, Csilla I, Szafron, Lukasz, Tan, Yen Y, Taylor, Jack A, Tea, Muy-Kheng, Teixeira, Manuel R, Teo, Soo-Hwang, Terry, Kathryn L, Thompson, Pamela J, Thomsen, Liv Cecilie Vestrheim, Thull, Darcy L, Tihomirova, Laima, Tinker, Anna V, Tischkowitz, Marc, Tognazzo, Silvia, Toland, Amanda Ewart, Tone, Alicia, Trabert, Britton, Travis, Ruth C, Trichopoulou, Antonia, Tung, Nadine, Tworoger, Shelley S, van Altena, Anne M, Van Den Berg, David, van der Hout, Annemarie H, van der Luijt, Rob B, Van Heetvelde, Mattias, Van Nieuwenhuysen, Els, van Rensburg, Elizabeth J, Vanderstichele, Adriaan, Varon-Mateeva, Raymonda, Vega, Ana, Edwards, Digna Velez, Vergote, Ignace, Vierkant, Robert A, Vijai, Joseph, Vratimos, Athanassios, Walker, Lisa, Walsh, Christine, Wand, Dorothea, Wang-Gohrke, Shan, Wappenschmidt, Barbara, Webb, Penelope M, Weinberg, Clarice R, Weitzel, Jeffrey N, Wentzensen, Nicolas, Whittemore, Alice S, Wijnen, Juul T, Wilkens, Lynne R, Wolk, Alicja, Woo, Michelle, Wu, Xifeng, Wu, Anna H, Yang, Hannah, Yannoukakos, Drakoulis, Ziogas, Argyrios, Zorn, Kristin K, Narod, Steven A, Easton, Douglas F, Amos, Christopher I, Schildkraut, Joellen M, Ramus, Susan J, Ottini, Laura, Goodman, Marc T, Park, Sue K, Kelemen, Linda E, Risch, Harvey A, Thomassen, Mads, Offit, Kenneth, Simard, Jacques, Schmutzler, Rita Katharina, Hazelett, Dennis, Monteiro, Alvaro N, Couch, Fergus J, Berchuck, Andrew, Chenevix-Trench, Georgia, Goode, Ellen L, Sellers, Thomas A, Gayther, Simon A, Antoniou, Antonis C, and Pharoah, Paul D P

Published
2017
Full Text
View/download PDF

47. Corrigendum to “Low-grade serous carcinoma (LGSC): A Canadian multicenter review of practice patterns and patient outcomes” [Gynecologic Oncology, Volume 157, Issue 1, April 2020, Pages 36–45]

Author

Scott, Stephanie A., primary, Fernandez, Marta Llaurado, additional, Kim, Hannah, additional, Elit, Laurie, additional, Nourmoussavi, Melica, additional, Glaze, Sarah, additional, Roberts, Lesley, additional, Offman, Saul L., additional, Rahimi, Kurosh, additional, Lytwyn, Alice, additional, Sur, Monalisa, additional, Gilks, C. Blake, additional, Matheson, Kara, additional, Köbel, Martin, additional, Dawson, Amy, additional, Tinker, Anna V., additional, Kwon, Janice S., additional, Hoskins, Paul, additional, Santos, Jennifer L., additional, Cheung, Andrea, additional, Provencher, Diane, additional, and Carey, Mark S., additional

Published
2022
Full Text
View/download PDF

48. 2022-RA-1198-ESGO Post hoc analysis of objective response rate by mismatch repair protein dimer loss/mutation status in patients with mismatch repair deficient endometrial cancer treated with dostarlimab

Author

Tinker, Anna V, primary, Sabatier, Renaud, additional, Gravina, Adriano, additional, Gilbert, Lucy, additional, Brown, Jubilee, additional, Samouëlian, Vanessa, additional, Reade, Clare J, additional, Mathews, Cara, additional, Ellard, Susan, additional, Banerjee, Susana, additional, Barretina-Ginesta, Maria Pillar, additional, Miller, Rowan, additional, Leath, Charles, additional, Pothuri, Bhavana, additional, Duan, Tao, additional, Han, Xinwei, additional, Zografos, Eleftherios, additional, Veneris, Jennifer, additional, and Oaknin, Ana, additional

Published
2022
Full Text
View/download PDF

49. 2022-RA-1194-ESGO Efficacy of dostarlimab in endometrial cancer by molecular subtype: a post hoc analysis of the GARNET study

Author

Tinker, Anna V, primary, Pothuri, Bhavana, additional, Gilbert, Lucy, additional, Sabatier, Renaud, additional, Brown, Jubilee, additional, Ghamande, Sharad, additional, Mathews, Cara, additional, O’Malley, David M, additional, Boni, Valentina, additional, Gravina, Adriano, additional, Banerjee, Susana, additional, Miller, Rowan E, additional, Pikiel, Joanna, additional, Mirza, Mansoor R, additional, Duan, Tao, additional, Han, Xinwei, additional, Zildjian, Sybil, additional, Zografos, Eleftherios, additional, Veneris, Jennifer, additional, and Oaknin, Ana, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results